
Director/PDMR Shareholding
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Shareholders approved the CIP at the Company's annual general meeting held on
2025 Awards
The Awards for FY25 are structured as an upfront tiered awards over shares under the CIP (in the form of conditional share awards), which will ultimately be delivered (subject to performance measures) in a combination of cash, deferred shares and deferred shares subject to an underpin and holding period.
1. |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||||||||||
(a) |
|
1) Alexander Scott 2)
|
||||||||||||||
2. |
Reason for the notification |
|||||||||||||||
(a) |
Position/status |
1) Chief Executive 2) Chief Financial Officer
|
||||||||||||||
(b) |
Initial notification/ Amendment |
Initial Notification |
||||||||||||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||||
(a) |
|
|
||||||||||||||
(b) |
LEI |
213800CYIZKXK9PQYE87 |
||||||||||||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||||||||||
(a) |
Description of the financial instrument, type of instrument |
Ordinary shares of |
||||||||||||||
|
Identification code |
ISIN: GB00BD45SH49 |
||||||||||||||
(b) |
Nature of the transaction |
Grant of conditional awards under the |
||||||||||||||
(c) |
Price(s) and volume (s) |
|
||||||||||||||
(d) |
Aggregated information - Aggregated volume - Price |
As stated above |
||||||||||||||
(e) |
Date of the transaction |
|
||||||||||||||
(f) |
Place of the transaction |
Outside a trading venue |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the